RYTM Q1 2022 Earnings — Rhythm Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

RYTMRhythm Pharmaceuticals, Inc.

$6B

Q1 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$1M+4180.0% YoY

Gross Profit

$1M84.6% margin

Operating Income

-$53M-3517.4% margin

Net Income

-$53M-3522.3% margin

EPS (Diluted)

$-1.05

QoQ Revenue Growth

-17.6%

Cash Flow

Operating Cash Flow

-$54M

Free Cash Flow

-$54M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$285M

Total Liabilities

$49M

Stockholders' Equity

$236M

Cash & Equivalents

$79M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1M	$35,000	+4180.0%
Gross Profit	$1M	$31,000	+3990.3%
Operating Income	-$53M	-$34M	-53.2%
Net Income	-$53M	$44M	-220.6%